Drugs / QRH-882260 Heptapeptide
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03438435 | Apr 2019 → Aug 2020 | cholangiocarcinoma | D. Kim Turgeon, MD | Completed | No outcome recorded |
| Phase 1 | NCT03148119 | Mar → Jul 2017 | colorectal cancer | Danielle Kim Turgeon | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QRH-882260 Heptapeptide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03438435 ↗ |
| Modality | Peptide | “fluorescently-labeled peptide composed of a 7-amino acid sequence” NCT03148119 ↗ |
| Route | Topical | “topical spray” NCT03148119 ↗ |